Biapenem (CLI 86815; L 627; LJC 10627) a parenteral carbapenem antibacterial agent with a broad spectrum.
Biapenem (CLI 86815) is a carbapenem antibiotic of in vitro antibacterial activity encompassing many Gramnegative and Gram-positive aerobic and anaerobic bacteria, including species producing β-lactamases. Biapenem (CLI 86815) is more stable than imipenem, mero-penem and panipenem to hydrolysis by human renal dihydropeptidase-I (DHP-I), and therefore does not require the coadministration of a DHP-I inhibitor. In randomised, nonblind or double-blind clinical trials, biapenem showed good clinical and bacteriological efficacy (similar to that of imipenem/ cilastatin) in the treatment of adult patients with intra-abdominal infections, lower respiratory infections or complicated urinary tract infections.
References:
[1]. Perry, C.M. and T. Ibbotson, Biapenem. Drugs, 2002. 62(15): p. 2221-34; discussion 2235.
[2]. Kasahara, S., et al., [Clinical effects of biapenem on febrile neutropenia in patients with hematological malignancy]. Jpn J Antibiot, 2008. 61(3): p. 115-21.